M-14015 Human Epididymis Protein 4 (HE-4) Quantitative Test Kit

Clinical Significance: Human Epididymis Protein 4 (HE4) is a novel tumor marker that ranks third among the most common gynecological malignancies. Due to its subtle early symptoms, ovarian cancer is often not easily detected in its initial stages. As the disease progresses, the 5-year survival rate for patients decreases from 70-90% to 20%. Therefore, early diagnosis is crucial for improving the cure rate of ovarian cancer.
Product Specifications: 20 tests per box
Product Shelf Life: Sealed in an aluminum foil bag, the product is valid for 18 months. Once opened, the aluminum foil bag should be used within 1 hour.
Product Storage: Store the test cards at 2°C to 30°C.
 
Usage Scenarios:
Hospitals and Oncology Departments: For early diagnosis and monitoring of ovarian cancer by tracking HE4 levels, significantly improving patient outcomes.
Gynecology Clinics: For regular screening of women at risk of ovarian cancer, especially those with subtle early symptoms.
Diagnostic Laboratories: For routine testing of serum HE4 levels as part of comprehensive cancer diagnostics and management programs.
Cancer Screening Programs: For early detection and monitoring of high-risk populations for ovarian cancer to improve survival rates.
Suitable Countries and Regions:
Developed Countries: United States, Canada, Western Europe (e.g., Germany, France, UK), Japan, Australia, etc., where advanced diagnostic tools are widely used for comprehensive cancer management and early detection.
Emerging Markets: China, India, Southeast Asia, Latin America, Eastern Europe, Middle East, etc., where healthcare systems are improving diagnostic capabilities for cancer and expanding access to modern diagnostic tools.
Global Health Programs: International health initiatives focused on enhancing cancer detection and management in low-resource settings.